(Albany, USA) DelveInsight’s ‘Checkpoint Inhibitors Competitive Landscape – 2023’ report provides comprehensive global coverage of available, marketed, and pipeline checkpoint inhibitor drugs in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the checkpoint inhibitors competitive domain.
Request for free sample page @ Checkpoint Inhibitors Competitive Landscape
Key Takeaways from the Checkpoint Inhibitors Competitive Landscape Report
Request a sample and discover the recent advances in the checkpoint inhibitors market @ Checkpoint Inhibitors Competitive Landscape Report
Checkpoint Inhibitors Overview
Checkpoint inhibitors are a type of immunotherapy. They obstruct proteins that prevent the immune system from attacking cancer cells. Cancer medications do not usually fit neatly into a specific form of treatment, and this is because certain medications function in multiple methods and belong to more than one class. Checkpoint inhibitors are frequently referred to as monoclonal antibodies or targeted treatments. The immune system protects humans from disease by killing germs and viruses, and t cells are the most common type of immune cell that achieves this.
Checkpoint inhibitors are drugs that suppress checkpoint proteins. They prevent proteins in cancer cells from pressing the stop button, and this activates the immune system, allowing T cells to locate and attack cancer cells. These medications inhibit the following checkpoint proteins: CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed cell death ligand 1). T cells express CTLA-4 and PD-1, and PD-L1 is found in cancer cells. These medications stimulate all immune cells, not just those that fight cancer. As a result, hyperactive T cells may have unintended consequences.
Find out more about FDA checkpoint inhibitors @ Checkpoint Inhibitor Drugs
Checkpoint Inhibitors Pipeline Analysis: Drug Profile
BCD-100: BIOCAD
Prolgolimab (BCD-100), developed by BIOCAD, is a completely human monoclonal antibody with PD-1 receptor specificity. It is an immunoglobulin G1 with L234A/L235A mutations that result in reduced affinity for Fc receptors. It is Eastern Europe’s first immune checkpoint inhibitor. In Russia, prolgolimab is already approved for the treatment of unresectable or metastatic melanoma. Prolgolimab is also being developed in combination with other medicines for the treatment of advanced NSCLC and cervical cancer as part of the Harmony clinical program. The drug is currently in Phase III development for the treatment of Non-Squamous Non-Small Cell Lung Neoplasm.
CBP501: CanBas Co., Ltd.
CanBas’s CBP501 is a novel calmodulin-modulating peptide with a well-defined multimodal anti-tumor function. This mode of action leads to increased platinum influx into and cytotoxicity to tumor cells, specifically, immunogenic cell death of tumor cells, suppression of M2 macrophage activity, reduced populations of cancer stem cells, and reduced migration/invasion by and epithelial-to-mesenchymal transition (EMT) of tumor cells even with short-term exposure treatment. CBP501 also improves the efficacy of some immune checkpoint inhibitors when combined with cisplatin or carboplatin. In the CT-26 syngeneic mice model, CBP501 and a platinum drug combined with anti-PD1, anti-PDL1, or anti-CTLA4 inhibit tumor growth while increasing CD8 T cells and decreasing M2 macrophages at tumor locations. The drug is currently in a Phase II clinical trial for the treatment of Stage IV pancreatic cancer.
Checkpoint Inhibitors Pipeline Drugs:
Learn more about the checkpoint inhibitor drugs @ Checkpoint Inhibitor Clinical Trials
Scope of the Checkpoint Inhibitors Competitive Landscape Report
Dive deep for rich insights into checkpoint inhibitor therapy; visit @ FDA-approved Checkpoint Inhibitors
Table of Contents
1.
Checkpoint Inhibitors Pipeline Report Introduction
2.
Checkpoint Inhibitors Pipeline Report Executive Summary
3.
Checkpoint Inhibitors Pipeline: Overview
4.
Marketed Checkpoint Inhibitors Drugs
4.1.
Pembrolizumab: Merck
5.
Checkpoint Inhibitors Clinical Trial Therapeutics
6.
Checkpoint Inhibitors Pipeline: Late-Stage Products (Pre-registration)
7.
Checkpoint Inhibitors Pipeline: Late-Stage Products (Phase III)
7.1.
8.
Checkpoint Inhibitors Pipeline: Mid-Stage Products (Phase II)
8.1.
9.
Checkpoint Inhibitors Pipeline: Early-Stage Products (Phase I)
9.1.
BEBT-260: BeBetter Med
10.
Checkpoint Inhibitors Pipeline Therapeutic Assessment
11.
Inactive Products in the Checkpoint Inhibitors Pipeline
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Unmet Needs
14.
Market Drivers and Barriers
15.
Appendix
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting
